Cargando…
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583872/ https://www.ncbi.nlm.nih.gov/pubmed/22971679 http://dx.doi.org/10.3892/ijo.2012.1626 |
_version_ | 1782475496128249856 |
---|---|
author | TADA, FUJIMASA ABE, MASANORI HIROOKA, MASASHI IKEDA, YOSHIOU HIASA, YOICHI LEE, YOON JUNG, NAM-CHUL LEE, WOO-BOK LEE, HYUN-SOO BAE, YONG-SOO ONJI, MORIKAZU |
author_facet | TADA, FUJIMASA ABE, MASANORI HIROOKA, MASASHI IKEDA, YOSHIOU HIASA, YOICHI LEE, YOON JUNG, NAM-CHUL LEE, WOO-BOK LEE, HYUN-SOO BAE, YONG-SOO ONJI, MORIKAZU |
author_sort | TADA, FUJIMASA |
collection | PubMed |
description | Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen (TAA)-pulsed DC vaccine in 5 patients with advanced HCC. DCs were generated by culturing blood monocytes in the presence of granulocyte macrophage-colony stimulating factor and interleukin-4 for 5 days. The DC vaccine was prepared by pulsing DCs with cytoplasmic transduction peptide-attached α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins and cultivating them in the presence of maturation cocktail. DCs were injected subcutaneously near the inguinal lymph nodes, followed by topical application of toll-like receptor-7 agonist around the injection site. We showed that our DC vaccine was safe and well-tolerated over 6 vaccinations in 5 patients. All 5 patients showed T cell responses against TAAs. Clinical benefit was observed in one of the 5 patients. In conclusion, the feasibility, safety and immune activity of DCs pulsed with TAAs were confirmed in HCC patients. However, clinical response was detected only in one patient. Future trials may consider applying this therapy in a less advanced stage to obtain better clinical responses. |
format | Online Article Text |
id | pubmed-3583872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-35838722013-03-04 Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma TADA, FUJIMASA ABE, MASANORI HIROOKA, MASASHI IKEDA, YOSHIOU HIASA, YOICHI LEE, YOON JUNG, NAM-CHUL LEE, WOO-BOK LEE, HYUN-SOO BAE, YONG-SOO ONJI, MORIKAZU Int J Oncol Articles Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen (TAA)-pulsed DC vaccine in 5 patients with advanced HCC. DCs were generated by culturing blood monocytes in the presence of granulocyte macrophage-colony stimulating factor and interleukin-4 for 5 days. The DC vaccine was prepared by pulsing DCs with cytoplasmic transduction peptide-attached α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins and cultivating them in the presence of maturation cocktail. DCs were injected subcutaneously near the inguinal lymph nodes, followed by topical application of toll-like receptor-7 agonist around the injection site. We showed that our DC vaccine was safe and well-tolerated over 6 vaccinations in 5 patients. All 5 patients showed T cell responses against TAAs. Clinical benefit was observed in one of the 5 patients. In conclusion, the feasibility, safety and immune activity of DCs pulsed with TAAs were confirmed in HCC patients. However, clinical response was detected only in one patient. Future trials may consider applying this therapy in a less advanced stage to obtain better clinical responses. D.A. Spandidos 2012-09-11 /pmc/articles/PMC3583872/ /pubmed/22971679 http://dx.doi.org/10.3892/ijo.2012.1626 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles TADA, FUJIMASA ABE, MASANORI HIROOKA, MASASHI IKEDA, YOSHIOU HIASA, YOICHI LEE, YOON JUNG, NAM-CHUL LEE, WOO-BOK LEE, HYUN-SOO BAE, YONG-SOO ONJI, MORIKAZU Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title | Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title_full | Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title_fullStr | Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title_full_unstemmed | Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title_short | Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
title_sort | phase i/ii study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583872/ https://www.ncbi.nlm.nih.gov/pubmed/22971679 http://dx.doi.org/10.3892/ijo.2012.1626 |
work_keys_str_mv | AT tadafujimasa phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT abemasanori phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT hirookamasashi phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT ikedayoshiou phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT hiasayoichi phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT leeyoon phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT jungnamchul phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT leewoobok phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT leehyunsoo phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT baeyongsoo phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma AT onjimorikazu phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma |